Summary
The global cancer market is poised for ongoing expansion with sales set to exceed $60bn by 2010. The emergence of novel molecular-targeted treatments will drive a significant proportion of R&D activity and future sales growth in this sector. While this will provide developers with ample opportunity for commercial reward, it will be fraught by a number of unique challenges.
Highlights
Targeted treatment will not entirely replace traditional cytotoxic treatment and the latter will continue to form the cornerstone of cancer therapy. However, the co-administration of targeted treatment will allow the optimization of cytotoxic doses and so drive the market for both classes over the coming years
Lifecycle management in the era of targeted treatment is becoming increasingly more challenging. The key to future success will be intensified by efforts to identify responsive patient populations at an earlier stage of the drug development process
Given the mechanistic differences between small molecules and antibodies, a logical approach is to combine these two drug classes. While this is an area of active clinical research, key to the success of this economically challenging approach is to identify the best combination of drugs and the patients that will benefit most from treatment
Scope
- Overview of the clinical and developmental challenges facing players in the oncology sector
- Expert insight into strategies for improving patient selection and optimizing "go and no-go" decisions in progressing late stage clinical development
- Lifecycle management case studies of key targeted therapy agents
- Strategies to overcome pharmacoeconomic challenges hindering the uptake of targeted treatment
Reasons to Purchase
- Understand the clinical and strategic challenges to the commercialization of targeted treatments
- Assess opportunities and risks for the continued development of innovative developmental treatments
- Adopt knowledge from this Analysis to drive strategic planning decisions in oncology drug development
|
